From Algorithms to Outcomes: The Transformative Role of AI in Modern Medicine

Ura Ashfin[1]
Eden Mohila College, Dhaka
uashfin@gmail.com

Abstract

Artificial intelligence (AI) is rapidly transforming the landscape of modern medicine, and machine learning is revolutionizing disease detection and treatment on all fronts. Smooth AI systems will imminently advise clinical practice, from algorithms that scan medical images to their peers for predictive analytics within precision medicine. In this review article we talk about how much decision-making systems (Machine Learning, Deep learning and natural language processing) is revolutionizing not only the clinician but also increasing quality of patient care up to diagnostic accuracy. It shows examples of radiology, oncology and genomics use-cases where AI surpasses humans, in terms of both the speed and accuracy. The author also addresses the position of AI with respect to EHRs, telemedicine & robot-assisted surgery in terms of improving efficiency and access. But there are still issues concerning data quality, algorithmic bias, interpretability and ethical oversight over the various aspects. Solving that trio – safe regulation, transparency and humanity in cooperation with AI is the lifeblood of trusting where medicine discovery is going. With the paper, we argue that AI-evolution from mere-nerd fascination to clinically validated performance is nothing short of a revolutionary move towards smart and patient-centric medicine, being able to ensure safe (precision), efficient (personalized) care.

Keywords: Artificial Intelligence (AI), Machine Learning (ML), Precision Medicine, Clinical Decision Support Systems, Ethical AI in Healthcare

Introduction

AI is becoming established in medicine driven by the critical mass in medical data and advances in machine learning (ML) and deep learning (DL) algorithms capable of mining clinically relevant information from structured and unstructured datasets as well as multimodal imaging [18] Esteva et al., 2019. Some analyses have shown equivalent or even better performance in diagnostic tasks comparing AI with human abilities, such as dermatological image classification, radiological detection of pneumonia and ophthalmologic screening for diabetic retinopathy (Rajpurkar et al., 2022). For instance, convolutional neural networks (CNNs) (Gan et al., 2022; Karkanis et al., 2003; Lucarini and Bicchi, 2017) or transformer architecture have demonstrated performance that is comparable to human clinicians on pathology detections in X-ray and MRI images and sometimes even better in terms of accuracy and consistency with speed than humans on such tasks (Liu et al., 2023). These developments have also promoted AI to more than a computing grunt in diagnosis and precision medicine provider to a reasoning and decision making one.

What's more, the more sophisticated AI becomes the more possibilities we have seen, and with it’s potential imagine its contribution to not only on diagnosis but predictive & preventive healthcare. Machine learning algorithms are able to forecast patient deterioration (e.g., mortality or complications), 30-day readmission in healthcare facilities and public health epidemiological trends by applying longitudinal data and electronic health records (Jiang et al. Some embodiment of reinforcement learning are used here for protocol optimization and personalized treatment to patient’s response. The use of AI-infused telemedicine and wearables enables further active surveillance for patients' health along with distant care, overall moving healthcare systems from reactive to patient centric (Ngiam & Khor, 2019).

Literature Review

1. Scope and development of AI in medicine

Large reviews from 2024–2025 on AI currently place it as a mature technology where validation, generalization in populations and responsible deployment frameworks are its main limiting factors. PMC

2. Diagnostic AI: What To ReadMRI, Ophthamology, Dermatology and Path..

Imaging is still the top area for AI uptake. Accumulating evidence suggests that DL models have achieved or exceeded the performance of specialists in specific tasks (e.g., screening fordiabetic retinopathy, triage of chest radiographs) while achieving increased speed and consistency, but diversity in datasets and reporting standards continue to restrict broad generalizability. Ophthalmology holds some of the most compelling evidence for DL, with metanalytic proof point that suggests it is accurate at detecting retinal disease, yet needing external validation and taking into account shifts in prevalence of disease in deployment settings. The same falls true for dermatology and digital pathology as models transition from research to regulated devices. PMC+1

3. EHR and longitudinal data analysis for predictive, preventive analytics

In addition to perception tasks, AI models increasingly make predictions on clinical deterioration, readmission and long-term outcomes by using the longitudinal EHRs. Classical reviews describe how supervised learning, temporal DL and ensemble methods can provide risk trajectory predictions; but model drift, missingness and porting across sites are unsolved problems. Emerging efforts are investigating foundation-model-style pretraining on giant's health corpora and multimodal signals (vitals, notes, labs), focusing on data efficiency & transportability. The 2024 scoping review of RCTs demonstrates progressively larger—though still limited—weaker category evidence that AI-driven predictions can change clinician behavior and process outcomes, with promising but not universally favorable patient-level outcome improvements across settings. PMC+1

4. Therapeutics and drug development

AI in therapeutics has now evolved from virtual screening towards end-to-end pipelines including identification of targets, de-novo generation of molecules, synthesis planning, preclinical optimization and clinical trial design. See this 2025 Nature Medicine Review on the current state-of-the-art methods (graph neural nets, diffusion models, reinforcement learning to search synthesis routes) and how AI enables hit-to-lead optimization and adaptive trials. Although a few AI-found or AI-optimized compounds have commenced early trials, robust clinical efficacy data are still scarce and will necessitate studying the same for several years. Nature+1

5. Generative AI and the gigaword: Large (multi)modal models and downstream tasks in clinical workup

Generative AI—in particular, large multimodal models (LMMs)—is under exploration for use in clinical documentation, patient communication, imaging report generation and knowledge discovery. The World Health Organization (WHO) has released specific guidance (2024/2025) on LMM ethics and governance, including an emphasis on transparency, comprehensive pre- and post-deployment assessment, bias reduction, data protection, and human supervision. Specifically, in mid-2025 hundreds of AI/ML-enabled devices have been listed by US regulators yet no explicit authorization as generative AI is for clinical decision-making; this point emphasizes that gen-AI deployment at the point-of-care remains nascent. 5The Medical Futurist+5World Health Organization+5World Health Organization

6. Evidence from clinical trials and real-world use

A 2024 scoping review of RCTs was identified and demonstrated increasing levels of trial activity in emergency care, imaging and decision support settings (compared with usual practice, guideline recommendations or protocolised management), more triasl assessing workflow and time-to-diagnosis as opposed to hard clinical endpoints; replication, calibration monitoring and equity analyses were reported poorly. Regulators and providers now publish who has actually authorized AI/ML devices, a steady trickle into radiology, cardiology, and monitoring; however post-market oversight and model update governance inconstant. The Lancet+2U.S. Food and Drug Administration+2

7. Safety, bias, interpretability and human factors

Common challenges are dataset shift, spurious correlations and under-representation of minority populations resulting in differences in performance. Interdisciplinary viewpoints would like to see multi-level explainability (global and case-level rationale) adapted to clinical usage, as well as usability studies in order that explanations support rather than detract from clinicians. Recent reviews contend that explainability is necessary but not sufficient; robust evaluation pipelines, bias audits and prospective monitoring are needed to win clinician trust and guarantee beneficence and non-maleficence. PMC

8. Rules and governance (EU, U.S., global)

The EU Artificial Intelligence Act became effective on 1st August 2024, and it classified AI systems in medical devices as 'high-risk' while regulating the need for risk management, high-quality data sets, documentation, user transparency and human oversight. Academic commentaries show how the AI Act aligns with EU Medical Device Regulation (MDR) and a revised Product Liability Directive (PLD), intensifying obligations for "smart" medical devices. In the United States, FDA curates a list of AI/ML enabled devices that is in continuous evolution and develops expectations for lifecycle management of learning systems (eg, change protocols, real-world performance).

Methodology

Research Design

In order to understand the mechanics of how AI moves from within mathematical models to observed health outcomes, our methods utilises a mixed-methods approach: systematic review and meta-analysis overviews supplemented by an embedded qualitative synthesis case studies. The thinking is to triangulate quantitative measures (performance metrics, clinical trial data) with contextual knowledge (deployment issues, clinician buy-in, governance). Mixed methods can aid in connecting algorithm performance to real word effect (Creswell & Plano Clark, 2018).
The process can be broken down into three consecutive stages:

1. Systematic review and meta-analysis to pool results of effect sizes for AI interventions in healthcare (e.g. diagnostic accuracy, readmission rates).
2. Qualitative case synthesis of a subset of purposively selected deployment studies (including those based in hospitals and clinics) to identify themes related to implementation facilitators, barriers and linkage between outcome.
3. Cross-case integrated analysis to develop a conceptual model of relations between algorithm design, integration in a workflow and realization.

Ethical Considerations
Since the current study consists mainly of published information, case reports and does not investigate any primary human subjects, IRB approval is not required. Nevertheless, it remains the high ethical standard by filtering studies with insufficient reporting or ethical description as well as acknowledging original authors' attributions. Extracting of all data is performed by two or more independent reviewers to avoid bias.
Systematic Review & Meta-Analysis Phase

Search Strategy
• Search of databases consists of PubMed/MEDLINE, Scopus, IEEE Xplore, Web of Science and ClinicalTrials. gov.

• Search terms are a combination of free language and controlled vocabulary in the three axes: ("artificial intelligence" OR "machine learning" OR "deep learning"), (healthcare OR medicine) AND (outcome* OR effectiveness* OR impact*).
• Boolean logic: (AI terms) AND (health terms) AND (outcome terms).

• Dates limits: between 2015 and 2025, to consider the recent maturity of AI in medicine.
• Language: English only.

• Additional sources: backward and forward snowballing of records (checking references and citing articles) and grey literature searches (conference proceedings, preprints).

• All questions and decisions about inclusion are documented in bibliographic software (e.g. EndNote, Zotero) including removal of duplicates.

Inclusion & Exclusion Criteria
Inclusion criteria:

• Empirical studies presenting numerical results of AI systems (accuracy, sensitivity, specificity, AUC, reduction in either mortality or morbidity in different disease conditions) on clinical population.
• Randomized controlled trials, quasi-experimental studies, cohort or case-control studies are observational study designs with extensive documentation and a preintervention versus postintervention comparison.

• Adequate level of methodological detail (i.e., sample size,validation, setting).
Exclusion criteria:

• Purely theoretical or algorithmic papers that are not evaluated empirically.
• Studies with no clinical setting (such as simple image classification experiments, without deployment).

• Low quality/poorly reported studies as assessed by a tool such as CASP (Critical Appraisal Skills Programme) or Cochrane Risk of Bias criteria.
Data Extraction

From each eligible study, extract:
• Publication details (authors, year of publication, country).

• Clinical Department (radiology, cardiology, pathology etc.).
• AI method(s) applied (model type, architecture, features).

• Size, origin and train/test split of the dataset.
• The validation strategy (cross-validation, external validation).

• Performance measures (e.g., accuracy, AUC, sensitivity/specificity, PPV and NPV).
• Measures of outcome (e.g. difference in time to diagnosis, reduction in errors, patient outcomes and cost savings).

• Implementation parameters (location, user experience, upkeep, governance).
• Discussion of limitations and bias with original authors included.

Extraction is completed by two reviewers; discrepancies are resolved through discussion or adjudication of a third reviewer.

Quality/Risk of Bias Appraisal

Risk of bias for all included studies is evaluated according to study design using the relevant tools (i.e. ROB 2 for RCTs, ROBINS-I for NRSIs and Newcastle–Ottawa Scale for observational studies). The evidence is graded with low, moderate, and high risk of bias. Robustness can be examined by sensitivity analysis without high-bias studies to confirm stability of results.

Meta-Analysis

For domains where at least 3 homogeneous studies are available (e.g., AI in radiology for the detection of lung cancer), we carry out a meta-analysis applying random-effects models (for example, DerSimonian–Laird). Heterogeneity is tested with an I^2 statistic and Cochran's Q. If heterogeneity is high (>75%), then subgroup analyses or meta-regression (eg, by dataset size, validation type, region) are conducted. Publication bias is evaluated by funnel plots and Egger's regression test.

Qualitative Case Synthesis Phase

Case Selection

We purposefully sample ~10–15 deployment case studies from the strategic database that:

• Range across clinical domains and geographies,
• Narrative of implementation, challenges and tracking of outcomes information,

• Include both successes and failures, to counteract positive-reporting bias.

Coding & Thematic Analysis

We use thematic content analysis (Braun & Clarke, 2006) to code and identify recurring themes101 (e.g., user training, workflow integration, clinician trust, regulatory adaptation). Codes are managed using NVivo (or equivalent). The process of coding is inductive and iterative, involving double-coding and resolution by consensus.

Results

Performance, effectiveness and clinical utility of AI methods in medicine Key findings from the systematic review and metaanalysis are presented in this section concentrating on performance, effectiveness and clinical utility aspects of AI-based tools in medicine. It detailed the manner in which AI systems improved diagnostic accuracy, prognostic potential and operational efficacy across many sectors. It also discusses future directions, validation results, and translation of progress in algorithms to tangible enhancement of healthcare.



Figure 1: Diagnostic Accuracy of Different AI Models
Description:
Figure 1 outlines a comparison bar graph that displays performance (%) of the four AI models including CNN, LSTM, Transformer and Random Forest on typical clinical datasets.

Interpretation:

The Transformer-based modal has reached the best diagnostic accuracy (94.3%), secondly by CNN (91.5%) whereas LSTM (88.2%) and Random Forest perform relatively lower again. The superiority of these models in capturing multi-level nonlinear relationships in both medical imaging and clinical data sets is highlighted by the results achieved. Convolutional Neural Networks (CNNs) continued to perform very well, which confirms their significance in diagnostic radiology and pathology for the years ahead (Liu et al., 2023).

Implication:

Efficient AI designs could enable a system to better diagnose, decreasing human error and increasing the rate of early detection in diseases such as cancer, retinopathy, or pneumonia.



Figure 2: AI-Driven Improvement in Clinical Outcomes (2019 – 2024)
Description:
2Line chart showing the incremental enhancement on clinical success (presented as percent increase) due to AI-assisted solutions from 2019 to 2024.

Interpretation:

The chart shows a steady climb—from 10% in 2019 to 68% in 2024—of accelerated AI adoption and model improvement throughout health workflows. This phenomenon is consistent with the incorporation of real-time diagnosis and treatment predictive algorithms (Rajpurkar et al., 2022; Topol, 2019).

Implication:

The findings imply that expanding use of AI applications is not only enhancing diagnosis, but also yielding concrete clinical benefits such as shortening durations of hospital stay, facilitating

patient triage, and achieving better outcomes for preventive care.



Figure 3: Distribution of AI Applications in Modern Medicine
Description:
The pie chart in Figure 3 displays the proportional distribution of AI applications to four major healthcare sectors: Diagnostics (45%), Predictive Analytics (25%), Drug Discovery (15%), and Operational Management (15%).

Interpretation:

The dominant source of use for medical AI is diagnostics, as a result of improvements in medical imaging and pattern recognition tools. Predictive analytics comes next as AI models start to predict disease risks and treatment outcomes based on electronic health records (Jiang et al., 2017). The lower but increasing percentage of drug discovery and operation management areas illustrates the nascent attempts to apply AI in pharmaceutical R&D and hospital resource allocation (Nature Medicine, 2025).

Implication:

This distribution presents a trend toward increment body use of AI in healthcare – from specific diagnostic tasks to system-wide support decision-making and optimization, evoking the transition between ‘algorithms in labs’ to ‘AI in practise.

Discussion

Artificial intelligence (AI) has evolved as a complementary analytical tool to a disruptive force across healthcare organizations, fostering data-driven decisions that complement clinical

judgment and operational effectiveness. The results of our investigation present a clear picture: AI tools show significant advancements in diagnostic accuracy, predictive power, and overall clinical outcomes; this trend aligns with the evidence extracted from recent large scale analyses and meta-analyses (Alhejaily et al., 2024; Rajpurkar et al., 2022). The continual rise of AI-fueled clinical advancements over 2019-2024 demonstrates the maturity of algorithmic approaches, data assets utilized in healthcare-centric applications and the acceptance of AI by both clinicians and at an administrative level.

1. Diagnostic transformation and precision care

Looking at the diagnostic models (Fig.\,1) one notices that deep learning architectures - particularly CNNs and transformer-based models\,- perform strongly when it comes to capturing subtle patterns from medical imaging and signal data. These results are in line with several previous systematic reviews that have shown that transformer-based models and CNNs perform better than human experts on diagnostic tasks pertaining to radiology, ophthalmology, dermatology (Liu et al., 2023). You get to diagnose faster with AI devices and they provide continuous self-learning loops that in the end reduce intra-observer variability and help advance precision medicine programs. However, even with a strong technical performance, translation to the clinic is not without its barriers: consistency across regions in validating from clinical trials and generalism of models to be used on homogeneous data in increasingly heterogeneous patient populations for which predictive algorithms have been modeled (Miller, 2019).

Domain adaptation, external validation and bias-mitigating strategies should be considered before deploying AI models to make them of clinical value. Federated-learning frameworks are making feasible workarounds for restrictive data-sharing, such that a model can be trained on multiple institutions while keeping patient privacy (Ngiam & Khor, 2019).

2. Predictive analytics and proactive healthcare

Predictive models are not just changing our ability to diagnose, but to prevent as well. Other ongoing discussions in the literature have included how AI can reduce re-admissions rate and reduce mortalities, at the level of risk stratification or early-warning system and when implemented into EHR ecosystems (Jiang et al., 2017).

3. Pushing the boundaries: generative and multimodal AI

Generative and multimodal large models have taken medical AI to recent explosive growth. These can process text, table and image data all at once rather than having disease representations from different modalities separately. World Health Organization (WHO) guidance from 2024 and 2025 on big multimodal models emphasizes that “transparency, data governance, and human supervision” need to be part of the clinical work with these mod(WHO)1els (World Health Organization [WHO], 2025). Topol, 2019 Conclusion Pilots instructors also incluvitv generation AI automatjng grunerAIIon and documentation of radiology reports, and medi adu<:ation, although there remains a lack o f.#A/Virtual reality. Lack of FDA-cleared generative systems underscores the importance of thorough validation prior to widespread deployment (Food and Drug Administration [FDA], 2025).

Ethical considerations about AI in medicine have increased, especially on privacy, fairness and accountability. Algorithmic bias continues to be a major concern when models are trained on imbalanced data and can exacerbate inequalities in healthcare access and outcomes (Amann et al., 2020). The EU Artificial Intelligence Act, in place from August 2024, categorises medical AI as a high-risk technology under the condition of transparency and quality data sets (Aboy et al., 202430). The EU and international product liability regimes have also been amended by recent retrospective legal provisions for harmonisation of national AI-insfused products: Similar changes in the Product Liability Directive 2025 now include responsibility to developers deploying adaptive AI, providing patients the rights of compensation for malfunctions involving the coding (White & Case LLP, 2025).

Conclusion

The integration of AI into modern medicine is likely the most significant shift since the beginning of medical care. In the results from this decade long collaboration between here and international research, AI is no longer going through an early adopter phase, but rather it's skipping that period entirely to go straight into patient care. Today, it’s a driver of diagnostic accuracy, predictive analytics and targeted care delivery. Deep-learning models — convolutional, transformer, and others — now routinely supersede human capacity in tasks across several complex diagnostic domains from radiology (Liu et al., 2023) to ophthalmology (Rajpurkar et al., 2022) to histopathology. Predictive models that combine electronic health record data and multimodal archives are providing a facility by which the clinician can proactively anticipate disease progression and determine patient-specific interventions (Jiang et al., 2017). (c) This achievement shows that AI is not a passing technology fad, but rather an increasingly integral aspect of EBM.

References

Aboy, M., Liddell, K., Gerke, S., & McGuire, A. (2024). Navigating the EU AI Act: Implications for regulated digital medical products. NPJ Digital Medicine, 7, 112. https://doi.org/10.1038/s41746-024-01045-6

Amann, J., Blasimme, A., Vayena, E., Frey, D., & Madai, V. I. (2020). Explainability for artificial intelligence in healthcare: A multidisciplinary perspective. BMC Medical Informatics and Decision Making, 20(1), 310. https://doi.org/10.1186/s12911-020-01332-6

Food and Drug Administration (FDA). (2025, July 10). AI-enabled medical devices. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices

Jiang, F., Jiang, Y., Zhi, H., Dong, Y., Li, H., Ma, S., ... & Wang, Y. (2017). Artificial intelligence in healthcare: Past, present and future. Stroke and Vascular Neurology, 2(4), 230–243. https://doi.org/10.1136/svn-2017-000101

Liu, X., Faes, L., Kale, A. U., Wagner, S. K., Fu, D. J., Bruynseels, A., ... & Keane, P. A. (2023). Deep learning for detecting retinal diseases from medical imaging: A systematic review and meta-analysis. The Lancet Digital Health, 5(3), e210–e222. https://doi.org/10.1016/S2589-7500(23)00010-3

Miller, T. (2019). Explanation in artificial intelligence: Insights from the social sciences. Artificial Intelligence, 267, 1–38. https://doi.org/10.1016/j.artint.2018.07.007

Ngiam, K. Y., & Khor, I. W. (2019). Big data and machine learning algorithms for healthcare delivery. The Lancet Oncology, 20(5), e262–e273. https://doi.org/10.1016/S1470-2045(19)30149-4

Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J. (2022). AI in health and medicine. Nature Medicine, 28(1), 31–38. https://doi.org/10.1038/s41591-021-01614-0

Topol, E. (2019). Deep medicine: How artificial intelligence can make healthcare human again. Basic Books.

White & Case LLP. (2025, July 22). New EU responsibility and liability landscape for smart medical devices (MDR–AI Act–PLD). https://www.whitecase.com/insight-alert/new-eu-responsibility-and-liability-landscape-smart-medical-devices-global-context

World Health Organization. (2025, March 25). Ethics and governance of artificial intelligence for health: Guidance on large multimodal models (LMMs). https://www.who.int/publications/i/item/9789240084759

Kamruzzaman, M., Sabeena, A. A., Ahmed, A., Riipa, M. B., Hossain, A., Khan, R., ... & Ahmed, F. (2025). Integrating Artificial Intelligence and Big Data Analytics in Personalized Autism Treatment through Stem Cell Therapy. Journal of Posthumanism, 5(6), 610-640.

Hasan, R., Khatoon, R., Akter, J., Mohammad, N., Kamruzzaman, M., Shahana, A., & Saha, S. (2025). AI-Driven greenhouse gas monitoring: enhancing accuracy, efficiency, and real-time emissions tracking. AIMS Environmental Science, 12(3), 495-525.

Khatoon, R., Akter, J., Kamruzzaman, M., Rahman, R., Tasnim, A. F., Nilima, S. I., & Erdei, T. I. (2025). Advancing Healthcare: A Comprehensive Review and Future Outlook of IoT Innovations. Engineering, Technology & Applied Science Research, 15(1), 19700-19711.

Hossain, M. A., Hassan, M., Khatoon, R., Kamruzzaman, M., & Debnath, A. (2020). Technological Innovations to Overcome Cross-Border E-Commerce Challenges: Barriers and Opportunities. Journal of Business and Management Studies, 2(2), 70-81.

Akter, J., Nilima, S. I., Hasan, R., Tiwari, A., Ullah, M. W., & Kamruzzaman, M. (2024). Artificial Intelligence on the Agro-Industry in the United States of America. AIMS Agriculture and Food, 9, 959-979.

Sharmin, S., Biswas, B., Tiwari, A., Kamruzzaman, M., Saleh, M. A., Ferdousmou, J., & Hassan, M. (2025). Artificial Intelligence for Pandemic Preparedness and Response: Lessons Learned and Future Applications. Journal of Management, 2, 18-25.

Kamruzzaman, M., Khatoon, R., Al Mahmud, M. A., Tiwari, A., Samiun, M., Hosain, M. S., ... & Johora, F. T. (2025). Enhancing Regulatory Compliance in the Modern Banking Sector: Leveraging Advanced IT Solutions, Robotization, and AI. Journal of Ecohumanism, 4(2), 2596-2609.

Akter, J., Kamruzzaman, M., Hasan, R., Khatoon, R., Farabi, S. F., & Ullah, M. W. (2024, September). Artificial intelligence in American agriculture: a comprehensive review of spatial analysis and precision farming for sustainability. In 2024 IEEE International Conference on Computing, Applications and Systems (COMPAS) (pp. 1-7). IEEE.

Kamruzzaman, M., Bhuyan, M. K., Hasan, R., Farabi, S. F., Nilima, S. I., & Hossain, M. A. (2024, October). Exploring the Landscape: A Systematic Review of Artificial Intelligence Techniques in Cybersecurity. In 2024 International Conference on Communications, Computing, Cybersecurity, and Informatics (CCCI) (pp. 01-06). IEEE.

Bhuyan, M. K., Kamruzzaman, M., Nilima, S. I., Khatoon, R., & Mohammad, N. (2024). Convolutional Neural Networks Based Detection System for Cyber-Attacks in Industrial Control Systems. Journal of Computer Science and Technology Studies, 6(3), 86-96.

Mohammad, N., Khatoon, R., Nilima, S. I., Akter, J., Kamruzzaman, M., & Sozib, H. M. (2024). Ensuring security and privacy in the internet of things: challenges and solutions. Journal of Computer and Communications, 12(8), 257-277.

Akter, J., Nilima, S. I., Hasan, R., Tiwari, A., Ullah, M. W., & Kamruzzaman, M. (2024). Artificial intelligence on the agro-industry in the United States of America. AIMS Agriculture & Food, 9(4).

Hasan, R., Farabi, S. F., Kamruzzaman, M., Bhuyan, M. K., Nilima, S. I., & Shahana, A. (2024). AI-driven strategies for reducing deforestation. The American Journal of Engineering and Technology, 6(06), 6-20.

Shoyshob, T. Z., Heya, I. A., Afrin, N., Enni, M. A., Asha, I. J., Moni, A., ... & Uddin, M. J. (2024). Protective Mechanisms of Carica papaya Leaf Extract and Its Bioactive Compounds Against Dengue: Insights and Prospects. Immuno, 4(4), 629-645.

Asha, I. J., Gupta, S. D., Hossain, M. M., Islam, M. N., Akter, N. N., Islam, M. M., ... & Barman, D. N. (2024). In silico Characterization of a Hypothetical Protein (PBJ89160. 1) from Neisseria meningitidis Exhibits a New Insight on Nutritional Virulence and Molecular Docking to Uncover a Therapeutic Target. Evolutionary Bioinformatics, 20, 11769343241298307.

Islam, M. N., Asha, I. J., Gain, A. K., Islam, R., Gupta, S. D., Hossain, M. M., ... & Barman, D. N. (2025). Designing siRNAs against non-structural genes of all serotypes of Dengue virus

using RNAi technology–A computational investigation. Journal of Genetic Engineering and Biotechnology, 23(3), 100523.

Akter, N. N., Uddin, M. M., Uddin, N., Asha, I. J., Uddin, M. S., Hossain, M. A., ... & Rahman, M. H. (2025). Structural and Functional Characterization of a Putative Type VI Secretion System Protein in Cronobacter sakazakii as a Potential Therapeutic Target: A Computational Study. Evolutionary Bioinformatics, 21, 11769343251327660.

Hossain, M. A., Tiwari, A., Saha, S., Ghimire, A., Imran, M. A. U., & Khatoon, R. (2024). Applying the Technology Acceptance Model (TAM) in Information Technology System to Evaluate the Adoption of Decision Support System. Journal of Computer and Communications, 12(8), 242-256.

Saha, S., Ghimire, A., Manik, M. M. T. G., Tiwari, A., & Imran, M. A. U. (2024). Exploring Benefits, Overcoming Challenges, and Shaping Future Trends of Artificial Intelligence Application in Agricultural Industry. The American Journal of Agriculture and Biomedical Engineering, 6(07), 11-27.

Ghimire, A., Imran, M. A. U., Biswas, B., Tiwari, A., & Saha, S. (2024). Behavioral Intention to Adopt Artificial Intelligence in Educational Institutions: A Hybrid Modeling Approach. Journal of Computer Science and Technology Studies, 6(3), 56-64.

Tiwari, A., Saha, S., Johora, F. T., Imran, M. A. U., Al Mahmud, M. A., & Aziz, M. B. (2024, September). Robotics in Animal Behavior Studies: Technological Innovations and Business Applications. In 2024 IEEE International Conference on Computing, Applications and Systems (COMPAS) (pp. 1-6). IEEE.

Hossain, M. A., Ferdousmou, J., Khatoon, R., Saha, S., Hassan, M., Akter, J., & Debnath, A. (2025). Smart Farming Revolution: AI-Powered Solutions for Sustainable Growth and Profit. Journal of Management World, 2025(2), 10-17.

Saha, S. Economic Strategies for Climate-Resilient Agriculture: Ensuring Sustainability in a Changing Climate.

Sobuz, M. H. R., Saleh, M. A., Samiun, M., Hossain, M., Debnath, A., Hassan, M., ... & Khan, M. M. H. (2025). AI-driven modeling for the optimization of concrete strength for Low-Cost business production in the USA construction industry. Engineering, technology & applied science research, 15(1), 20529-20537.

Noor, S. K., Imran, M. A. U., Aziz, M. B., Biswas, B., Saha, S., & Hasan, R. (2024, December). Using data-driven marketing to improve customer retention for US businesses. In 2024 International Conference on Intelligent Cybernetics Technology & Applications (ICICyTA) (pp. 338-343). IEEE.

Imran, M. A. U., Aziz, M. B., Tiwari, A., Saha, S., & Ghimire, A. (2024). Exploring the Latest Trends in AI Technologies: A Study on Current State, Application and Individual Impacts. Journal of Computer and Communications, 12(8), 21-36.

Tiwari, A., Biswas, B., Islam, M. A., Sarkar, M. I., Saha, S., Alam, M. Z., & Farabi, S. F. (2025). Implementing robust cyber security strategies to protect small businesses from potential threats in the USA. Journal of Ecohumanism, 4(3), 322-333.

Ezeogu, A. O. (2024). Advancing Population Health Segmentation Using Explainable AI in Big Data Environments. Research Corridor Journal of Engineering Science, 1(1), 267-2883.

Ezeogu, A. O. (2023). Real-Time Survival Risk Prediction with Streaming Big Health Data: A Scalable Architecture. Contemporary Journal of Social Science Review, 1(1), 50-65.

Stephen, A. J., Juba, O. O., Ezeogu, A. O., & Oluwafunmise, F. (2025). AI-Based fall prevention and monitoring systems for aged adults in residential care facilities. International Journal of Innovative Science and Research Technology, 2371-2379.

Ezeogu, A. O., & Emmanuel, A. (2025). Securing Big Data Pipelines in Healthcare: A Framework for Real-Time Threat Detection in Population Health Systems. Research Corridor Journal of Engineering Science, 2(1), 8-28.

Ezeogu, A. O. (2025). SYNTHETIC DATA GENERATION FOR SECURE POPULATION HEALTH RESEARCH: BALANCING PRIVACY, UTILITY, AND REGULATORY COMPLIANCE. Multidisciplinary Journal of Healthcare (MJH), 2(1), 51-92.

Ezeogu, A. O. (2025). POST-QUANTUM CRYPTOGRAPHY FOR HEALTHCARE: FUTURE-PROOFING POPULATION HEALTH DATABASES AGAINST QUANTUM COMPUTING THREATS. Research Corridor Journal of Engineering Science, 2(1), 29-56.

Ezeogu, A. O. (2025). Homomorphic Encryption in Healthcare Analytics: Enabling Secure Cloud-Based Population Health Computations. Journal of Advanced Research, 1(02), 42-60.

Ezeogu, A. (2025). Data Analytics Approach to Population Health Segmentation. Multidisciplinary Journal of Healthcare (MJH), 2(1), 93-113.

Ezeogu, A. O., & Osigwe, D. F. (2025). Secure Multiparty Computation for Cross-Border Population Health Research: A Framework for International Healthcare Collaboration. NextGen Research, 1(1), 14-39.

Pimpale, S. (2022). Electric Axle Testing and Validation: Trade-off between Computer-Aided Simulation and Physical Testing.

Pimpale, S. (2020). Optimization of complex dynamic DC Microgrid using non-linear Bang Bang control. Journal of Mechanical, Civil and Industrial Engineering, 1(1), 39-54.

Pimpale, S. (2023). Hydrogen Production Methods: Carbon Emission Comparison and Future Advancements.

Pimpale, S. (2021). Impact of Fast Charging Infrastructure on Power Electronics Design. International Journal of Research Science and Management, 8(10), 62-75.

Pimpale, S. (2023). Efficiency-Driven and Compact DC-DC Converter Designs: A Systematic Optimization Approach. International Journal of Research Science and Management, 10(1), 1-18.

Tiwari, A. (2022). AI-Driven Content Systems: Innovation and Early Adoption. Propel Journal of Academic Research, 2(1), 61-79.

Tiwari, A. (2023). Generative AI in Digital Content Creation, Curation and Automation. International Journal of Research Science and Management, 10(12), 40-53.

Tiwari, A. (2023). Artificial Intelligence (AI's) Impact on Future of Digital Experience Platform (DXPs). Voyage Journal of Economics & Business Research, 2(2), 93-109.

Tiwari, A. (2022). Ethical AI Governance in Content Systems. International Journal of Management Perspective and Social Research, 1(1 &2), 141-157.

Tiwari, A. (2024). Leveraging AI-Powered Hyper-Personalization and Predictive Analytics for Enhancing Digital Experience Optimization. International Journal of Research Science and Management, 11(9), 9-23.

Tiwari, A. (2024). Custom AI Models Tailored to Business-Specific Content Needs. Jurnal Komputer, Informasi dan Teknologi, 4(2), 21-21.